INmune Bio Reports $45.9M Loss in 2025 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy INMB?
Source: Yahoo Finance
- Increased Financial Loss: INmune Bio reported a net loss of approximately $45.9 million for the year ended December 31, 2025, up from $42.1 million in 2024, indicating ongoing challenges in R&D and market promotion that may affect investor confidence.
- Decline in R&D Expenses: Research and development expenses for 2025 were approximately $20.7 million, significantly down from $33.2 million in 2024, suggesting a reduction in spending on the Alzheimer's trial, which could impact funding priorities for future projects.
- Intangible Asset Impairment: The company recorded a full impairment of $16.5 million for its intangible assets in 2025 due to the Alzheimer's trial failing to meet clinical endpoints, which may negatively affect future financing and partnership opportunities.
- Cash Flow Position: As of December 31, 2025, INmune Bio had approximately $24.8 million in cash and cash equivalents, sufficient to fund operations through Q1 2027, but still needs to seek additional funding to support late-stage development projects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INMB
Wall Street analysts forecast INMB stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.130
Low
8.00
Averages
8.00
High
8.00
Current: 1.130
Low
8.00
Averages
8.00
High
8.00
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INmune Bio Reports $45.9M Loss in 2025 Earnings
- Increased Financial Loss: INmune Bio reported a net loss of approximately $45.9 million for the year ended December 31, 2025, up from $42.1 million in 2024, indicating ongoing challenges in R&D and market promotion that may affect investor confidence.
- Decline in R&D Expenses: Research and development expenses for 2025 were approximately $20.7 million, significantly down from $33.2 million in 2024, suggesting a reduction in spending on the Alzheimer's trial, which could impact funding priorities for future projects.
- Intangible Asset Impairment: The company recorded a full impairment of $16.5 million for its intangible assets in 2025 due to the Alzheimer's trial failing to meet clinical endpoints, which may negatively affect future financing and partnership opportunities.
- Cash Flow Position: As of December 31, 2025, INmune Bio had approximately $24.8 million in cash and cash equivalents, sufficient to fund operations through Q1 2027, but still needs to seek additional funding to support late-stage development projects.
See More
INmune Bio Reports Disappointing FY Results
- Financial Performance: INmune Bio reported a FY GAAP EPS of -$1.86, missing expectations by $0.11, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: Despite a 400% year-over-year revenue increase to $0.05 million, the figure fell short of market expectations by $0.01 million, reflecting difficulties in market expansion that could limit future cash inflows.
- Clinical Trial Progress: The discussion around INmune Bio's XPro1595 Phase II MINDFuL results and registrational strategy for Alzheimer's disease highlights the company's ongoing investment in R&D, although it has yet to translate into financial gains in the short term.
- Market Performance: INmune Bio is rated as lagging behind the market in Seeking Alpha's quant ratings, indicating investor concerns regarding its future growth potential, which may lead to downward pressure on its stock price.
See More
INmune Bio Reports Financial Results for FY 2025
- Financial Performance: INmune Bio reported a net loss of approximately $45.9 million for FY 2025, an increase from $42.1 million in FY 2024, indicating ongoing pressure from R&D and operational expenses that may impact future funding capabilities.
- R&D Progress: The CORDStrom™ platform is on track to submit a Marketing Authorization Application (MAA) to the UK’s MHRA by mid-summer 2026, followed by EMA and FDA submissions, marking a significant milestone in the commercialization process of a key product.
- Clinical Trial Results: XPro™ has made new advancements in Alzheimer's disease clinical trials, with the FDA approving its progression to an adaptive Phase 2b/3 registrational pathway, indicating a clearer strategic positioning in the precision medicine landscape.
- Capital Operations: In 2025, the company raised $27.5 million through the sale of 4,304,707 shares of common stock, with cash reserves expected to last through Q1 2027, reflecting a cautious and forward-looking approach to capital allocation.
See More
INmune Bio to Announce FY Earnings on March 30
- Earnings Announcement Date: INmune Bio (INMB) is set to release its FY earnings on March 30 after market close, with a consensus EPS estimate of -$0.27, reflecting an 87.2% year-over-year improvement, indicating potential financial performance enhancement.
- Significant Revenue Growth Expected: The revenue is projected to reach $0.06 million, marking a staggering 500.0% year-over-year increase, which suggests substantial growth in the company's products or services and may bolster investor confidence moving forward.
- Estimate Revision Dynamics: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates experienced one upward revision with no downward adjustments, indicating a cautiously optimistic outlook from analysts regarding the company's future performance.
- Clinical Trial Progress: INmune Bio recently discussed the Phase II MINDFuL results of XPro1595 and its registration strategy for Alzheimer's disease, demonstrating the company's ongoing commitment to R&D and responsiveness to market needs.
See More
INmune Bio Hosts Webinar on Alzheimer's Treatment Pathway
- Clinical Trial Progress: Following the completion of the MINDFuL Phase 2 trial, INmune Bio has received FDA feedback supporting the advancement of XPro1595 to a registrational study in Alzheimer's patients, marking a significant milestone in early Alzheimer's treatment.
- Webinar Topics: The upcoming webinar will focus on three core topics: MINDFuL trial results, registrational study design, and FDA feedback, aiming to provide participants with in-depth insights into the clinical and commercial potential of XPro™.
- Expert Participation: The webinar will feature renowned clinical experts from Australia and Canada who will share their experiences and insights from the MINDFuL trial, further enhancing the company's authority in Alzheimer's research.
- Global Partnership Strategy: INmune Bio plans to maximize XPro™'s clinical and commercial potential through global partnerships, accelerating its development for Alzheimer's patients, which reflects the company's keen insight into market demands.
See More
INmune Bio to Host CORDStrom Webinar on RDEB Treatment
- Clinical Trial Results: INmune Bio will host a webinar on February 26, 2026, to share the latest clinical trial results of CORDStrom for treating recessive dystrophic epidermolysis bullosa (RDEB), particularly its systemic disease-modifying capabilities, which is expected to attract significant attention.
- Efficacy Data Presentation: The webinar will highlight new data on CORDStrom's impact on key clinical benchmarks such as improvements in EBDASI skin scores, weight gain in pediatric patients, and reductions in clinical symptoms, showcasing its potential to enhance patients' quality of life.
- Expert Participation: The event will feature firsthand clinical observations from principal investigators of the MissionEB trial, including UK dermatology expert Dr. Anna Martinez and INmune Bio's Chief Scientific Officer Prof. Mark Lowdell, adding credibility to the discussions.
- CORDStrom Platform Overview: CORDStrom is a patent-pending cell medicine derived from human umbilical cord mesenchymal stem cells, designed to provide high-quality, consistent treatment options with broad potential indications, which may play a crucial role in treating complex inflammatory and autoimmune diseases.
See More
INmune Bio Reports $45.9M Loss in 2025 Earnings
- Increased Financial Loss: INmune Bio reported a net loss of approximately $45.9 million for the year ended December 31, 2025, up from $42.1 million in 2024, indicating ongoing challenges in R&D and market promotion that may affect investor confidence.
- Decline in R&D Expenses: Research and development expenses for 2025 were approximately $20.7 million, significantly down from $33.2 million in 2024, suggesting a reduction in spending on the Alzheimer's trial, which could impact funding priorities for future projects.
- Intangible Asset Impairment: The company recorded a full impairment of $16.5 million for its intangible assets in 2025 due to the Alzheimer's trial failing to meet clinical endpoints, which may negatively affect future financing and partnership opportunities.
- Cash Flow Position: As of December 31, 2025, INmune Bio had approximately $24.8 million in cash and cash equivalents, sufficient to fund operations through Q1 2027, but still needs to seek additional funding to support late-stage development projects.
See More
INmune Bio Reports Disappointing FY Results
- Financial Performance: INmune Bio reported a FY GAAP EPS of -$1.86, missing expectations by $0.11, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: Despite a 400% year-over-year revenue increase to $0.05 million, the figure fell short of market expectations by $0.01 million, reflecting difficulties in market expansion that could limit future cash inflows.
- Clinical Trial Progress: The discussion around INmune Bio's XPro1595 Phase II MINDFuL results and registrational strategy for Alzheimer's disease highlights the company's ongoing investment in R&D, although it has yet to translate into financial gains in the short term.
- Market Performance: INmune Bio is rated as lagging behind the market in Seeking Alpha's quant ratings, indicating investor concerns regarding its future growth potential, which may lead to downward pressure on its stock price.
See More
INmune Bio Reports Financial Results for FY 2025
- Financial Performance: INmune Bio reported a net loss of approximately $45.9 million for FY 2025, an increase from $42.1 million in FY 2024, indicating ongoing pressure from R&D and operational expenses that may impact future funding capabilities.
- R&D Progress: The CORDStrom™ platform is on track to submit a Marketing Authorization Application (MAA) to the UK’s MHRA by mid-summer 2026, followed by EMA and FDA submissions, marking a significant milestone in the commercialization process of a key product.
- Clinical Trial Results: XPro™ has made new advancements in Alzheimer's disease clinical trials, with the FDA approving its progression to an adaptive Phase 2b/3 registrational pathway, indicating a clearer strategic positioning in the precision medicine landscape.
- Capital Operations: In 2025, the company raised $27.5 million through the sale of 4,304,707 shares of common stock, with cash reserves expected to last through Q1 2027, reflecting a cautious and forward-looking approach to capital allocation.
See More
INmune Bio to Announce FY Earnings on March 30
- Earnings Announcement Date: INmune Bio (INMB) is set to release its FY earnings on March 30 after market close, with a consensus EPS estimate of -$0.27, reflecting an 87.2% year-over-year improvement, indicating potential financial performance enhancement.
- Significant Revenue Growth Expected: The revenue is projected to reach $0.06 million, marking a staggering 500.0% year-over-year increase, which suggests substantial growth in the company's products or services and may bolster investor confidence moving forward.
- Estimate Revision Dynamics: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates experienced one upward revision with no downward adjustments, indicating a cautiously optimistic outlook from analysts regarding the company's future performance.
- Clinical Trial Progress: INmune Bio recently discussed the Phase II MINDFuL results of XPro1595 and its registration strategy for Alzheimer's disease, demonstrating the company's ongoing commitment to R&D and responsiveness to market needs.
See More
INmune Bio Hosts Webinar on Alzheimer's Treatment Pathway
- Clinical Trial Progress: Following the completion of the MINDFuL Phase 2 trial, INmune Bio has received FDA feedback supporting the advancement of XPro1595 to a registrational study in Alzheimer's patients, marking a significant milestone in early Alzheimer's treatment.
- Webinar Topics: The upcoming webinar will focus on three core topics: MINDFuL trial results, registrational study design, and FDA feedback, aiming to provide participants with in-depth insights into the clinical and commercial potential of XPro™.
- Expert Participation: The webinar will feature renowned clinical experts from Australia and Canada who will share their experiences and insights from the MINDFuL trial, further enhancing the company's authority in Alzheimer's research.
- Global Partnership Strategy: INmune Bio plans to maximize XPro™'s clinical and commercial potential through global partnerships, accelerating its development for Alzheimer's patients, which reflects the company's keen insight into market demands.
See More
INmune Bio to Host CORDStrom Webinar on RDEB Treatment
- Clinical Trial Results: INmune Bio will host a webinar on February 26, 2026, to share the latest clinical trial results of CORDStrom for treating recessive dystrophic epidermolysis bullosa (RDEB), particularly its systemic disease-modifying capabilities, which is expected to attract significant attention.
- Efficacy Data Presentation: The webinar will highlight new data on CORDStrom's impact on key clinical benchmarks such as improvements in EBDASI skin scores, weight gain in pediatric patients, and reductions in clinical symptoms, showcasing its potential to enhance patients' quality of life.
- Expert Participation: The event will feature firsthand clinical observations from principal investigators of the MissionEB trial, including UK dermatology expert Dr. Anna Martinez and INmune Bio's Chief Scientific Officer Prof. Mark Lowdell, adding credibility to the discussions.
- CORDStrom Platform Overview: CORDStrom is a patent-pending cell medicine derived from human umbilical cord mesenchymal stem cells, designed to provide high-quality, consistent treatment options with broad potential indications, which may play a crucial role in treating complex inflammatory and autoimmune diseases.
See More
